Moderna, Inc.
MRNANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 31, 2026Score 5/30567% above fair value
$220.83−0.89 (-0.40%)
Close on Nov 2, 2026Market cap $88.16BP/E –Yield –
Moderna Deferred revenue — Non-current by Quarter
Deferred revenue — Non-current ($M) ($M)
Moderna Deferred revenue — Non-current: $147M in Q2 2026, up 126.2% from a year earlier.
Latest, Q2 2026
147
Period ended Jun 30, 2026
Change on a year earlier
+126.2%
65 in Q2 2025
History
31 quarters
Since Q4 2018
Sources
30
Documents cited below
Where the Q2 2026 figure comes from
Source: Form 10-Q (filed 2026-07-31) ↗
Reported in Form 10-Q / 10-K Consolidated Balance Sheets.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Moderna Deferred revenue — Non-current ($M), quarterly Q4 2018–Q2 2026 [Data set]. Compiled from Moderna SEC filings and investor materials. https://stockdatahq.com/stocks/mrna/kpis/def-rev-nc
See every metric in the Moderna KPI table. Data updated Nov 3, 2026.